Our mission is to produce clinically relevant and rigorous research. Our vision is produce high quality research according to the following equation:
A photo-sensible drug area is topically administrated to the vulnerable plaque and activated on site with light induction. Activated cytotoxic agents will promote plaque sealing and scaring of potential plaques to rupture by depletion of macrophages and lipid content and substitution with SMC and collagen.
We chose to regenerate the heart “not because it is easy, but because it is hard, because that challenge we are willing to accept, one we are unwilling to postpone, and one which we intend to achive”. This adaptation of JF Kennedy’s great speech “we chose to go to the moon” (1962) matches with the rapidly growing field of cardiac cell therapy.
The maladaptive remodeling is the hallmark of chronic heart failure post myocardial infarction. Currently, no curative treatment exists. Cardiac cell therapy has not met all expectation to cure myocardial infarction. Refining the treatment and understanding of mechanism are of paramount to define optimal and efficient therapy.
We investigate new cardiac cell therapy based on Concomitant implantation of cells and exogenous matrix for cardiac regeneration and myocardial contractility recovery.
laque instability and thrombus formation precedes coronary occlusion. In particular plaque vulnerability is believed to play an important role in the pathogenesis. Alternatively, coronary artery occlusion could be triggered by different mechanisms such as thromboembolism.
We perform histological characterization of retrieved material (Movat pentachrome, H&E, TMG, HRP, oil red O,...) after aspiration during percutaneous coronary intervention and investigate the correlation between thrombi composition and etiology of sudden occlusive coronary thrombosis.
HFR 01 - 12-019
+41 26 306 3800